Randomised clinical trial: The safety and efficacy of long-acting octreotide in patients with portal hypertension

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 8, 2012, Pages 904-912

  Chandok, N ^a,b   Kamath, P S ^a   Blei, A ^c   Bosch, J ^d   Carey, W ^e   Grace, N ^f   Kowdley, K V ^g   Benner, K ^h   Groszmann, R J ⁱ  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^d HOSPITAL CLÍNIC   (Spain)

^e LERNER RESEARCH INSTITUTE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g VIRGINIA MASON MEDICAL CENTER   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; LONG ACTING DRUG; OCTREOTIDE; PLACEBO;

ABDOMINAL CRAMP; ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; BILIARY COLIC; CHILD PUGH CLASS A; CHILD PUGH CLASS B; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS VARICES; FEMALE; FLATULENCE; GLUCAGON BLOOD LEVEL; HEMODYNAMIC PARAMETERS; HEPATIC VEIN PRESSURE GRADIENT; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INJECTION SITE PAIN; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; MALE; MORBIDITY; MULTICENTER STUDY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPERIOR MESENTERIC ARTERY PULSATILITY INDEX;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HALF-LIFE; HEPATIC VEINS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OCTREOTIDE; PORTAL VEIN; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84858800635     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05050.x     Document Type: Article

References (18)

1. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W,. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-38.
2. Qureshi W, Adler DG, Davila R, et al,. ASGE guideline: the role of endoscopy in the management of variceal hemorrhage, updated July 2005. Gastrointest Endosc 2005; 62: 651-5.
3. Jalan R, Hayes PC,. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. Gut 2000; 46: III1-15.
4. Albillos A, Rossi I, Iborra J, et al,. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994; 21: 88-94.
5. McCormick PA, Biagini MR, Dick R, et al,. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology 1992; 16: 1180-6.
6. Jenkins SA, Baxter JN, Critchley M, et al,. Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ 1997; 315: 1338-41.
7. Spahr L, Giostra E, Frossard JL, Morard I, Mentha G, Hadengue A,. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. Am J Gastroenterol 2007; 102: 1397-405.
8. Ottesen LH, Flyvbjerg A, Jakobsen P, Bendtsen F,. The pharmacokinetics of octreotide in cirrhosis and in healthy man. J Hepatol 1997; 26: 1018-25.
9. Gillis JC, Noble S, Goa KL,. Octreotide long-acting release (LAR) A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997; 53: 681-99.
10. Groszmann RJ, Glickman M, Blei AT, Storer E, Conn HO,. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology 1979; 76: 253-8.
11. Buonamico P, Sabba C, Garcia-Tsao G, et al,. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: a double-blind randomized echo-Doppler study. Hepatology 1995; 21: 134-9.
12. Sabba C, Ferraioli G, Genecin P, et al,. Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans: an operator-blind echo-Doppler study. Hepatology 1991; 13: 714-8.
13. Escorsell A, Bandi JC, Andreu V, et al,. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120: 161-9.
14. Baik SK, Jeong PH, Ji SW, Yoo BS, Kim SK, Lee DK, et al,. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005; 100: 631-5.
15. Moller S, Brinch K, Henriksen JH, et al,. Effect of octreotide on systemic, central and splanchnic hemodynamics in cirrhosis. J Hepatol 1997; 26: 1026-33.
16. Albraldes JG, Bosch J,. Sandostatin and analogues in portal hypertension. Hepatology 2002; 25: 1305-12.
17. Malesci A, Taccon M, Valentini A, Basilico M, Lorenzano E, Salerno F,. Octreotide long-term treatment in patients with portal hypertension: persistent intubation of postprandial glucagon response without major change in renal function. J Hepatol 1997; 26: 816-25.
18. Chatila R, Ferayorni L, Gupta T, Groszmann RJ,. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatology 2000; 31: 572-6.